Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FURIN_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FURIN_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FURIN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FURIN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FURIN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FURIN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FURIN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006465 | Colorectum | AD | signal peptide processing | 10/3918 | 14/18723 | 6.90e-05 | 1.11e-03 | 10 |
GO:0051604 | Colorectum | AD | protein maturation | 85/3918 | 294/18723 | 6.73e-04 | 6.91e-03 | 85 |
GO:0071635 | Colorectum | AD | negative regulation of transforming growth factor beta production | 8/3918 | 12/18723 | 7.99e-04 | 7.91e-03 | 8 |
GO:0007178 | Colorectum | AD | transmembrane receptor protein serine/threonine kinase signaling pathway | 99/3918 | 355/18723 | 9.92e-04 | 9.28e-03 | 99 |
GO:0071559 | Colorectum | AD | response to transforming growth factor beta | 74/3918 | 256/18723 | 1.45e-03 | 1.23e-02 | 74 |
GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
GO:0006869 | Colorectum | AD | lipid transport | 108/3918 | 398/18723 | 1.67e-03 | 1.39e-02 | 108 |
GO:0071560 | Colorectum | AD | cellular response to transforming growth factor beta stimulus | 72/3918 | 250/18723 | 1.85e-03 | 1.52e-02 | 72 |
GO:0007179 | Colorectum | AD | transforming growth factor beta receptor signaling pathway | 59/3918 | 198/18723 | 1.94e-03 | 1.58e-02 | 59 |
GO:1990000 | Colorectum | AD | amyloid fibril formation | 15/3918 | 34/18723 | 1.96e-03 | 1.58e-02 | 15 |
GO:0033619 | Colorectum | AD | membrane protein proteolysis | 21/3918 | 57/18723 | 4.16e-03 | 2.88e-02 | 21 |
GO:0071634 | Colorectum | AD | regulation of transforming growth factor beta production | 16/3918 | 41/18723 | 6.20e-03 | 3.88e-02 | 16 |
GO:0016485 | Colorectum | AD | protein processing | 63/3918 | 225/18723 | 6.77e-03 | 4.19e-02 | 63 |
GO:0032801 | Colorectum | AD | receptor catabolic process | 12/3918 | 28/18723 | 7.21e-03 | 4.39e-02 | 12 |
GO:00421761 | Colorectum | SER | regulation of protein catabolic process | 126/2897 | 391/18723 | 5.33e-17 | 2.52e-14 | 126 |
GO:19033621 | Colorectum | SER | regulation of cellular protein catabolic process | 91/2897 | 255/18723 | 1.22e-15 | 5.36e-13 | 91 |
GO:00160321 | Colorectum | SER | viral process | 118/2897 | 415/18723 | 8.36e-12 | 1.65e-09 | 118 |
GO:00457321 | Colorectum | SER | positive regulation of protein catabolic process | 77/2897 | 231/18723 | 9.91e-12 | 1.90e-09 | 77 |
GO:00098961 | Colorectum | SER | positive regulation of catabolic process | 132/2897 | 492/18723 | 4.16e-11 | 6.72e-09 | 132 |
GO:00458621 | Colorectum | SER | positive regulation of proteolysis | 106/2897 | 372/18723 | 8.40e-11 | 1.20e-08 | 106 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FURIN | SNV | Missense_Mutation | novel | c.2167N>T | p.Ala723Ser | p.A723S | P09958 | protein_coding | tolerated(0.14) | benign(0.247) | TCGA-A2-A04R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
FURIN | SNV | Missense_Mutation | novel | c.1492C>A | p.Arg498Ser | p.R498S | P09958 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
FURIN | SNV | Missense_Mutation | | c.356N>A | p.Pro119His | p.P119H | P09958 | protein_coding | tolerated(0.25) | possibly_damaging(0.572) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
FURIN | SNV | Missense_Mutation | novel | c.1956N>C | p.Gln652His | p.Q652H | P09958 | protein_coding | tolerated(0.42) | benign(0.005) | TCGA-B6-A40B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FURIN | SNV | Missense_Mutation | | c.1874N>T | p.Thr625Met | p.T625M | P09958 | protein_coding | tolerated(0.22) | benign(0.02) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FURIN | SNV | Missense_Mutation | novel | c.245C>A | p.Pro82Gln | p.P82Q | P09958 | protein_coding | deleterious(0.02) | benign(0.027) | TCGA-OL-A6VR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FURIN | insertion | Frame_Shift_Ins | novel | c.547dupC | p.Gln183ProfsTer9 | p.Q183Pfs*9 | P09958 | protein_coding | | | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FURIN | SNV | Missense_Mutation | novel | c.158N>A | p.Gly53Glu | p.G53E | P09958 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FURIN | SNV | Missense_Mutation | novel | c.958N>A | p.Ala320Thr | p.A320T | P09958 | protein_coding | tolerated(1) | benign(0.05) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FURIN | SNV | Missense_Mutation | novel | c.2167N>A | p.Ala723Thr | p.A723T | P09958 | protein_coding | tolerated(0.16) | benign(0.089) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | inhibitor | 252166802 | | |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | | US9266828, E | | |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | inhibitor | 178103178 | | |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | | US9266828, B | | |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | inhibitor | 252166868 | | |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | | US9266828, C | | |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | inhibitor | 252166858 | | |